All In Biotech

Drug Trial Radar · NCT00184600

Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes

A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin Versus a Twice Daily Insulin Mixture Versus a Meal-time Rapid-Acting Insulin in Subjects With Type 2 Diabetes Inadequately Controlled on Therapy With Oral Agents, and Assessing the Requirement for More Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, Their Efficacy and Durability

Last checked: Nov 20, 2026Latest source record: Mar 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 708 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

708

Actual

Start

Nov 2004

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current OAD (oral anti-diabetic drug) treatment in subjects with type 2 diabetes and to verify the safety of use (number and severity of episodes of hypoglycaemia, body weight and side effects).

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • biphasic insulin aspartDrug

    Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart

  • insulin detemirDrug

    Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart

  • insulin aspartDrug

    Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c (Glycosylated Haemoglobin) at Month 12Time frame: Baseline, Month 12
  2. HbA1c (Glycosylated Haemoglobin) at Month 36Time frame: Baseline, Month 36

Locations

63 sites in 2 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Dublin, Ireland

  • Novo Nordisk Investigational Site

    Dublin, Ireland

  • Novo Nordisk Investigational Site

    Dublin, Ireland

  • Novo Nordisk Investigational Site

    Galway, Ireland

  • Novo Nordisk Investigational Site

    Aberdeen, United Kingdom

  • Novo Nordisk Investigational Site

    Addlestone, United Kingdom

  • Novo Nordisk Investigational Site

    Airdrie, United Kingdom

  • Novo Nordisk Investigational Site

    Ashton-under-Lyne, United Kingdom

  • Novo Nordisk Investigational Site

    Ayr, United Kingdom

  • Novo Nordisk Investigational Site

    Belfast, United Kingdom

  • Novo Nordisk Investigational Site

    Belfast, United Kingdom

  • Novo Nordisk Investigational Site

    Belfast, United Kingdom

  • Novo Nordisk Investigational Site

    Berkshire, United Kingdom

  • Novo Nordisk Investigational Site

    Birmingham, United Kingdom

  • Novo Nordisk Investigational Site

    Birmingham, United Kingdom

  • Novo Nordisk Investigational Site

    Bournemouth, United Kingdom

  • Novo Nordisk Investigational Site

    Bradford, United Kingdom

  • Novo Nordisk Investigational Site

    Bristol, United Kingdom

  • Novo Nordisk Investigational Site

    Bury St Edmunds, United Kingdom

  • Novo Nordisk Investigational Site

    Cambridge, United Kingdom

  • Novo Nordisk Investigational Site

    Colchester, United Kingdom

  • Novo Nordisk Investigational Site

    Coventry, United Kingdom

  • Novo Nordisk Investigational Site

    Crawley, United Kingdom

  • Novo Nordisk Investigational Site

    Derby, United Kingdom

  • Novo Nordisk Investigational Site

    Dundee, United Kingdom

  • Novo Nordisk Investigational Site

    Edinburgh, United Kingdom

  • Novo Nordisk Investigational Site

    Exeter, United Kingdom

  • Novo Nordisk Investigational Site

    Gillingham, United Kingdom

  • Novo Nordisk Investigational Site

    Glasgow, United Kingdom

  • Novo Nordisk Investigational Site

    Guildford, United Kingdom

  • Novo Nordisk Investigational Site

    Haywards Heath, United Kingdom

  • Novo Nordisk Investigational Site

    Headington, United Kingdom

  • Novo Nordisk Investigational Site

    High Wycombe, United Kingdom

  • Novo Nordisk Investigational Site

    Hull, United Kingdom

  • Novo Nordisk Investigational Site

    Kettering, United Kingdom

  • Novo Nordisk Investigational Site

    Leeds, United Kingdom

  • Novo Nordisk Investigational Site

    Leicester, United Kingdom

  • Novo Nordisk Investigational Site

    Leicester, United Kingdom

  • Novo Nordisk Investigational Site

    Liverpool, United Kingdom

  • Novo Nordisk Investigational Site

    Liverpool, United Kingdom

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.